Respiratory DiseaseNCT05648227
Validation of an Artificial Intelligence Enabled Diagnostic Support Software (ArtiQ.Spiro) in Primary Care Spirometry Datasets - a Retrospective Analysis
An observational study of Respiratory Disease, run by Royal Brompton & Harefield NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
A retrospective study to evaluate the diagnostic performance of an Artificial Intelligence enabled software (ArtiQ.Spiro) in UK primary care spirometry datasets. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Respiratory Disease
- How many people
- 1,000 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 1 Jul 2022to 28 Feb 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The datasets, which will be analysed retrospectively, will comprise spirometry data previously collected as part of clinical spirometry pathways in primary care.
Who may be able to join
- Adult aged 18 years or over
- At least one of the following respiratory symptoms: cough, wheeze, shortness of breath, reduced exercise tolerance
- Spirometry performed for clinical purposes in a non-hospital lung function setting (such as a community clinic, a GP practice, or at home)
- Spirometry was supervised by a doctor or non-medical allied health professional
Who cannot join
- Aged 17 or under
- No respiratory symptoms
- Spirometry performed for pre-operative assessment
- Spirometry performed exclusively as part of a research study
- Spirometry performed at home without supervision.
Trial locations and contacts
1 site in 1 country.
About this study
A retrospective study to evaluate the diagnostic performance of an Artificial Intelligence enabled software (ArtiQ.Spiro) in UK primary care spirometry datasets.
Read the detailed description
This is a retrospective analysis of existing clinical datasets with consecutive spirometry collected in a primary care setting in the UK. Individual patient data will be included if the individual meets the study protocol eligibility criteria.
Clinical datasets will be de-identified (name, date of birth, address, postcode, occupation GP, ethnicity, medications data removed). Individuals will be identified by a study ID number. The de-identified datasets will contain the minimum information needed for spirometry and ArtiQ.Spiro - namely age, smoking history, height, weight, primary respiratory symptom - and the deidentified data exported from the primary care spirometry software.
ArtiQ.Spiro Evaluation (Index Tests for Diagnosis and Quality):
A deidentified dataset will be provided to a machine learning analyst who will apply the machine learning algorithm of ArtiQ.Spiro. For each individual, the algorithm will produce a preferred diagnosis (highest probability diagnostic category) (Index Test for Diagnosis) and an assessment of spirometry quality (Acceptable, Usable, Not Acceptable/Usable) (Index Test for Quality). No clinical information outside of the spirometry dataset nor reference standard data will be made available to the analyst.
Reference Standard for Diagnosis:
The clinical dataset, together with available primary care records and secondary care records, will be used by the senior members of the direct clinical care team (Consultants in Respiratory Medicine with an interest in integrated respiratory care) to provide a reference standard for diagnosis. For each individual, two consultants will provide a diagnosis independently and blinded to the index test (ArtiQ.Spiro) output. If there is agreement, this diagnosis will be taken as the reference standard for diagnosis for the individual. If there is no agreement, a third consultant outside the direct clinical care team will be provided with the same information (but deidentified) to act as final arbitrator.
Reference Standard for Quality:
A deidentified dataset will be provided to a specialist respiratory physiologist. He/she will grade the quality of each spirometric session according to the official American Thoracic Society / European Respiratory Society 2019 Technical Statement for Standardization of Spirometry. For each patient, the quality of the spirometry session will be graded according to one of three categories: Acceptable, Usable, Not Acceptable/Usable. This will act as the reference standard for quality. The respiratory physiologists will be blinded to the output from the Index Test (ArtiQ.Spiro). The respiratory physiologists will also record time taken to evaluate the dataset.
Data Analysis:
Data analysis will be performed by the research team who will be independent to the direct clinical care team and the respiratory physiologists who will be providing the reference standards for diagnosis and quality respectively.
- Conditions
- Respiratory Disease
- Medical subject headings
- Respiration Disorders
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluate diagnostic performance of an Artificial Intelligence enabled software (ArtiQ.Spiro) in UK primary care spirometry datasets.
Evaluate diagnostic performance of an Artificial Intelligence enabled software (ArtiQ.Spiro) in UK care spirometry datasets.
Measured: 24 months
Secondary outcomes (1)
To evaluate the performance of an Artificial Intelligence enabled software (ArtiQ.Spiro) in the quality grading of Forced Expiratory Volume in One second (FEV1) and Forced Vital Capacity (FVC) from UK primary care spirometry datasets.
Measured: 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Dec 2022
- Study start1 Jul 2022
- Primary completion1 Feb 2025 (estimated)
- Study completion28 Feb 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Respiratory DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Royal Brompton & Harefield NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Collaborators
- The Hillingdon Hospitals NHS Foundation Trust, University of Leicester, Southern Health NHS Foundation Trust, Imperial College London, Queen Mary University of London, King's College London, Papworth Hospital NHS Foundation Trust, King's College Hospital NHS Trust
- Responsible party
- Sponsor
- Investigators
- William Man, FRCP, Principal investigator, Royal Brompton & Harefield Hospitals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05648227
- Sponsor's protocol ID
- 314058
- Status last verified
- Nov 2024
- First submitted
- 5 Dec 2022
- Last updated
- 31 Jan 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Validation of an Artificial Intelligence Enabled Diagnostic Support Software (ArtiQ.Spiro) in Primary Care Spirometry Datasets - a Retrospective Analysis
- ClinicalTrials.gov ID
- NCT05648227
- Acronym / sponsor ID
- 314058
- Conditions
- Respiratory Disease
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- Royal Brompton & Harefield NHS Foundation TrustUniversity, hospital or other
- Collaborators
- The Hillingdon Hospitals NHS Foundation Trust, University of Leicester, Southern Health NHS Foundation Trust, Imperial College London, Queen Mary University of London, King's College London, Papworth Hospital NHS Foundation Trust, King's College Hospital NHS Trust
- Study start
- 1 Jul 2022 (actual)
- Primary completion
- 1 Feb 2025 (estimated)
- Study completion
- 28 Feb 2025 (estimated)
- First posted
- 13 Dec 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A retrospective study to evaluate the diagnostic performance of an Artificial Intelligence enabled software (ArtiQ.Spiro) in UK primary care spirometry datasets.
Detailed description
This is a retrospective analysis of existing clinical datasets with consecutive spirometry collected in a primary care setting in the UK. Individual patient data will be included if the individual meets the study protocol eligibility criteria.
Clinical datasets will be de-identified (name, date of birth, address, postcode, occupation GP, ethnicity, medications data removed). Individuals will be identified by a study ID number. The de-identified datasets will contain the minimum information needed for spirometry and ArtiQ.Spiro - namely age, smoking history, height, weight, primary respiratory symptom - and the deidentified data exported from the primary care spirometry software.
ArtiQ.Spiro Evaluation (Index Tests for Diagnosis and Quality):
A deidentified dataset will be provided to a machine learning analyst who will apply the machine learning algorithm of ArtiQ.Spiro. For each individual, the algorithm will produce a preferred diagnosis (highest probability diagnostic category) (Index Test for Diagnosis) and an assessment of spirometry quality (Acceptable, Usable, Not Acceptable/Usable) (Index Test for Quality). No clinical information outside of the spirometry dataset nor reference standard data will be made available to the analyst.
Reference Standard for Diagnosis:
The clinical dataset, together with available primary care records and secondary care records, will be used by the senior members of the direct clinical care team (Consultants in Respiratory Medicine with an interest in integrated respiratory care) to provide a reference standard for diagnosis. For each individual, two consultants will provide a diagnosis independently and blinded to the index test (ArtiQ.Spiro) output. If there is agreement, this diagnosis will be taken as the reference standard for diagnosis for the individual. If there is no agreement, a third consultant outside the direct clinical care team will be provided with the same information (but deidentified) to act as final arbitrator.
Reference Standard for Quality:
A deidentified dataset will be provided to a specialist respiratory physiologist. He/she will grade the quality of each spirometric session according to the official American Thoracic Society / European Respiratory Society 2019 Technical Statement for Standardization of Spirometry. For each patient, the quality of the spirometry session will be graded according to one of three categories: Acceptable, Usable, Not Acceptable/Usable. This will act as the reference standard for quality. The respiratory physiologists will be blinded to the output from the Index Test (ArtiQ.Spiro). The respiratory physiologists will also record time taken to evaluate the dataset.
Data Analysis:
Data analysis will be performed by the research team who will be independent to the direct clinical care team and the respiratory physiologists who will be providing the reference standards for diagnosis and quality respectively.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The datasets, which will be analysed retrospectively, will comprise spirometry data previously collected as part of clinical spirometry pathways in primary care.
Key inclusion criteria (4 listed)
- Adult aged 18 years or over
- At least one of the following respiratory symptoms: cough, wheeze, shortness of breath, reduced exercise tolerance
- Spirometry performed for clinical purposes in a non-hospital lung function setting (such as a community clinic, a GP practice, or at home)
- Spirometry was supervised by a doctor or non-medical allied health professional
Key exclusion criteria (5 listed)
- Aged 17 or under
- No respiratory symptoms
- Spirometry performed for pre-operative assessment
- Spirometry performed exclusively as part of a research study
- Spirometry performed at home without supervision.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Evaluate diagnostic performance of an Artificial Intelligence enabled software (ArtiQ.Spiro) in UK primary care spirometry datasets.
Time frame: 24 months
Evaluate diagnostic performance of an Artificial Intelligence enabled software (ArtiQ.Spiro) in UK care spirometry datasets.
1 secondary outcome
To evaluate the performance of an Artificial Intelligence enabled software (ArtiQ.Spiro) in the quality grading of Forced Expiratory Volume in One second (FEV1) and Forced Vital Capacity (FVC) from UK primary care spirometry datasets.
Time frame: 24 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Jan 2025.
- Individual participant dataSharing planned: No
Related trials for Respiratory Disease
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Not yet recruitingObservational study
Effectiveness and Efficiency of Home Telemonitoring and Non-invasive Ventilation in Patients With COPD and Hypercapnia (EVALECO)
Pulmonary Disease, Chronic Obstructive (COPD), Hypercapnia
RecruitingPhase 1
A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese Volunteers
Healthy Participants
Not yet recruitingPhase 2
Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)
Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV)
RecruitingPhase 2
Phase 2b Efficacy and Safety Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients
COPD, Chronic Obstructive Pulmonary Disease (COPD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
William Man, FRCP principal investigator
Royal Brompton & Harefield Hospitals
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Respiratory Disease, run by Royal Brompton & Harefield NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 31 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluate diagnostic performance of an Artificial Intelligence enabled software (ArtiQ.Spiro) in UK primary care spirometry datasets. (time frame: 24 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jan 2025; AzTrials last refreshed its copy on 29 Oct 2026.